Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from NVAX

3 Under-the-Radar Stocks That Could Be Tomorrow's Blue Chips

Investors will increasingly focus on upcoming economic data to gauge soft landing odds that have helped drive stock performance in 2024. Given an evolving macroeconomic landscape, it could be wise to invest in under-the-radar socks Workday (WDAY), CrowdStrike (CRWD), and Novavax (NVAX), which could be tomorrow’s blue chips. Read more.

StockNews.com

Novavax Surges After FDA Signs Off On Its Updated Covid Shot, Joining Pfizer, Moderna

The Food and Drug Administration signed off on Novavax's updated Covid booster late Tuesday, and NVAX stock surged just before the close.

Investors Business Daily

Novavax Rockets 28% On Upbeat Sales View, Cuts Workforce By A Quarter

Novavax an offered upbeat sales view Tuesday and announced a 25% reduction in its workforce to help cut costs — and NVAX stock rocketed.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Novavax Plummets On Downgrade: Is It The Covid Engine That Couldn't?

Novavax has a solid platform but continues to face a $700 million litigation headwind, an analyst said Thursday as he downgraded NVAX stock.

Investors Business Daily

2 Biotech Stocks That Are Screaming “SELL ME!”

The biotech sector is witnessing the headwinds from the banking crisis, layoffs, and the Inflation Reduction Act. So, fundamentally weak biotech stocks Ginkgo Bioworks Holdings (DNA) and Novavax (NVAX) might be best avoided. Read on.

StockNews.com

Novavax Stock Plummets On 'Substantial Uncertainty' For Its Future

Novavax says there's "substantial doubt" regarding its ability to continue, and NVAX stock crashed Wednesday.

Investors Business Daily

Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip

Novavax plans to update its Covid vaccine for new variants, and NVAX stock outperformed its vaccine stock rivals.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Biotech Firestorm Takes Down Novavax Despite Quadrupled Sales

Novavax posted an unexpected third-quarter loss, and NVAX stock yo-yoed Wednesday despite better-than-expected sales.

Investors Business Daily

Why Novavax's Uphill Battle Continues Despite Winning U.S. Booster Authorization

Novavax won Food and Drug Administration for its Covid booster on Wednesday, but NVAX stock dipped slightly in response.

Investors Business Daily

Novavax Stock Plummets As 'Market Dynamics' Crush Its 2022 Sales Outlook

Novavax widely missed second-quarter forecasts Tuesday, leading the Covid vaccine maker to slash its guidance and NVAX stock to crash.

Investors Business Daily

Is Novavax a Buy, Sell, or Hold Following FDA Decision?

Despite the FDA authorization of Novavax’s (NVAX) two-dose vaccine, the possible side effects and slow vaccine uptake keep the stock under pressure. So, let’s evaluate if it is worth adding the stock to one’s portfolio now. Read on….

StockNews.com

Novavax (NVAX) Down As EU Adds Side Effects To COVID Jab Label

Shares of Novavax (NASDAQ: NVAX) fell 26.2% on Jul 14, after the European Medicines Agency's (TSE: EMA) Pharmacovigilance Risk Assessment Committee ("PRAC") updated the product label of Nuvaxovid, the company's COVID-19 vaccine, to include some potential side effects like severe aller

Benzinga

Novavax Tanks On New Troubles For Its Newly Authorized Covid Vaccine

The FDA authorized Novavax's Covid vaccine for emergency use, but NVAX stock tumbled on Thursday on warnings facing the two-dose regimen.

Investors Business Daily

Will Novavax's Covid Booster Thesis Play Out? What The Survey Says

Novavax's Covid booster is preemptively gaining steam, according to the July IBD/TIPP Poll. The results come as NVAX stock climbs.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

IBD/TIPP Poll: There's Bad News For Novavax's Covid Vaccine

Novavax could struggle to find a U.S. market for its Covid shot, according to the latest IBD/TIPP Poll as NVAX stock continues to flounder.

Benzinga

Novavax' Sees Conditional Approval Of COVID-19 Vaccine Booster In Australia As US FDA Delays Its Decision

The Australian regulatory authority has conditionally approved Novavax Inc's (NASDAQ:NVAX) Nuvaxovid (NVX-CoV2373) COVID-19 vaccine as a booster in individuals aged 18 and over. The provisional registration was based on data from Novavax's Phase 2 trial conducted in Australia, wherein a single booster dose of Nuvaxovid was administered to healthy adult participants approximately six months after…

Investors Business Daily

Novavax Dive Continues As FDA Reviews New Covid Shot Information

Three days after the FDA's advisors recommended Novavax's Covid shot, the agency had yet to make a move, and NVAX stock toppled.

Benzinga

Why Novavax Stock Is Falling Today

Novavax Inc (NASDAQ: NVAX) shares are trading lower Thursday following reports that the U.S. Food and Drug Administration's decision on the company's COVID-19 vaccine could be delayed to review manufacturing changes.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

HC Wainwright Says Non-mRNA COVID-19 Option Underappreciated

HC Wainwright says safety concerns were noted for Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine, but the strength of data showed that benefit outweighs risks.

Benzinga

Why Novavax Stock Is Trading Higher Today

Novavax Inc (NASDAQ: NVAX) shares are trading higher Wednesday after a committee of independent U.S. Food and Drug Administration (FDA) vaccine advisors voted to recommend Novavax's COVID-19 vaccine for Emergency Use Authorization (EUA).

Benzinga

Novavax's COVID-19 Vaccine For Adults Over 18 Backed By FDA Advisors: What's Next?

Novavax, Inc. (NASDAQ: NVAX) announced the U.S.

Benzinga

What's Going On With Novavax Stock Today?

Novavax Inc (NASDAQ: NVAX) shares have been halted since the pre-market session as the U.S. Food and Drug Administration holds a meeting to determine the fate of the company's COVID-19 vaccine.

Investors Business Daily

Novavax Stock Jumps After FDA Advisors Endorse Its Covid Shot

An FDA panel voted nearly unanimously in favor of Novavax's Covid shot on Tuesday. After yo-yoing Wednesday, NVAX stock settled up.

Investors Business Daily

Novavax Crashes After FDA Suggests Its Covid Vaccine Causes Heart Inflammation

Benzinga

$100 Invested In Novavax 5 Years Ago Would Be Worth This Much

Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 9.78% on an annualized basis producing an average annual return of 19.75%. Currently, Novavax has a market capitalization of $3.69 billion.

1 2 3

People

Jerome Powell

2,786 stories

Mangeet Kaur BounsMangeet

595 stories

Brendan Smith

31 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

the Food and Drug Administration

135 stories

WDAY

96 stories

European Medicines Agency

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.